PROCAPS GROUP SA

PROCAPS GROUP SA (PROC)

$4.27

+0.02

(+0.47%)

Market is closed - opens 7 PM, 30 May 2023

Insights on PROCAPS GROUP SA

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 112.42M → 81.19M (in $), with an average decrease of 9.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 22.58M → -4.25M (in $), with an average decrease of 59.4% per quarter

  • Vs NBIX

    In the last 1 year, Procaps Group S.A has experienced a drawdown of -46.7%, however Neurocrine Biosciences, Inc. resisted the overall trend and outperformed by 45.0%

Performance

  • $4.15
    $4.29
    $4.27
    downward going graph

    2.81%

    Downside

    Day's Volatility :3.27%

    Upside

    0.47%

    downward going graph
  • $3.68
    $9.50
    $4.27
    downward going graph

    13.82%

    Downside

    52 Weeks Volatility :61.26%

    Upside

    55.05%

    downward going graph

Returns

PeriodPROCAPS GROUP SASector (Health Care)Index (Russel 2000)
3 Months
1.67%
0.3%
-6.7%
6 Months
-34.21%
-6.1%
-3.7%
1 Year
-49.82%
-4.8%
-6.3%
3 Years
-58.14%
23.8%
26.9%

Highlights

Market Capitalization
479.5M
Book Value
- $0.01
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.43
PE Ratio
9.88
Wall Street Target Price
7.0
Profit Margin
10.38%
Operating Margin TTM
13.43%
Return On Assets TTM
7.46%
Return On Equity TTM
46.32%
Revenue TTM
409.9M
Revenue Per Share TTM
4.05
Quarterly Revenue Growth YOY
-19.8%
Gross Profit TTM
191.3M
EBITDA
62.9M
Diluted Eps TTM
0.43
Quarterly Earnings Growth YOY
-0.63
EPS Estimate Current Year
0.33
EPS Estimate Next Year
0.43
EPS Estimate Current Quarter
-0.04
EPS Estimate Next Quarter
0.06

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for PROCAPS GROUP SA(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 63.93%

Current $4.27
Target $7.00

Company Financials

FY19Y/Y Change
Revenue
324.8M
-
Net Income
-17.0M
-
Net Profit Margin
-5.24%
-
FY20Y/Y Change
Revenue
331.5M
↑ 2.06%
Net Income
-10.4M
↓ 38.58%
Net Profit Margin
-3.15%
↑ 2.09%
FY21Y/Y Change
Revenue
409.7M
↑ 23.61%
Net Income
-100.9M
↑ 865.47%
Net Profit Margin
-24.62%
↓ 21.47%
FY22Y/Y Change
Revenue
409.9M
↑ 0.04%
Net Income
42.5M
↓ 142.18%
Net Profit Margin
10.38%
↑ 35.0%
Q4 FY21Q/Q Change
Revenue
126.5M
↑ 18.45%
Net Income
-46.3M
↑ 25.37%
Net Profit Margin
-36.58%
↓ 2.02%
Q1 FY22Q/Q Change
Revenue
85.6M
↓ 32.33%
Net Income
16.4M
↓ 135.53%
Net Profit Margin
19.21%
↑ 55.79%
Q2 FY22Q/Q Change
Revenue
112.4M
↑ 31.29%
Net Income
-6.9M
↓ 142.07%
Net Profit Margin
-6.15%
↓ 25.36%
Q3 FY22Q/Q Change
Revenue
110.4M
↓ 1.79%
Net Income
22.6M
↓ 426.35%
Net Profit Margin
20.45%
↑ 26.6%
Q4 FY22Q/Q Change
Revenue
81.2M
↓ 26.45%
Net Income
-4.3M
↓ 118.83%
Net Profit Margin
-5.24%
↓ 25.69%
Q1 FY23Q/Q Change
Revenue
81.2M
↑ 0.0%
Net Income
-4.3M
↑ 0.0%
Net Profit Margin
-5.24%
↑ 0.0%
FY19Y/Y Change
Total Assets
337.7M
-
Total Liabilities
581.7M
-
FY20Y/Y Change
Total Assets
359.5M
↑ 6.46%
Total Liabilities
614.2M
↑ 5.59%
FY21Y/Y Change
Total Assets
462.1M
↑ 28.54%
Total Liabilities
500.5M
↓ 18.52%
FY22Y/Y Change
Total Assets
460.2M
↓ 0.42%
Total Liabilities
462.1M
↓ 7.67%
Q4 FY21Q/Q Change
Total Assets
462.1M
↓ 0.56%
Total Liabilities
500.5M
↑ 16.81%
Q1 FY22Q/Q Change
Total Assets
483.3M
↑ 4.57%
Total Liabilities
502.9M
↑ 0.49%
Q2 FY22Q/Q Change
Total Assets
470.2M
↓ 2.71%
Total Liabilities
499.8M
↓ 0.63%
Q3 FY22Q/Q Change
Total Assets
471.2M
↑ 0.21%
Total Liabilities
481.7M
↓ 3.62%
Q4 FY22Q/Q Change
Total Assets
84.4M
↓ 82.08%
Total Liabilities
145.4M
↓ 69.81%
Q1 FY23Q/Q Change
Total Assets
84.4M
↑ 0.0%
Total Liabilities
145.4M
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
68.3M
-
Investing Cash Flow
-12.1M
-
Financing Cash Flow
-46.9M
-
FY20Y/Y Change
Operating Cash Flow
70.9M
↑ 3.86%
Investing Cash Flow
-17.1M
↑ 41.61%
Financing Cash Flow
-40.5M
↓ 13.72%
Q4 FY21Q/Q Change
Operating Cash Flow
6.3M
↑ 0.0%
Investing Cash Flow
-4.2M
↑ 0.0%
Financing Cash Flow
-10.2M
↑ 0.0%
Q1 FY22Q/Q Change
Operating Cash Flow
6.3M
↑ 0.0%
Investing Cash Flow
-4.2M
↑ 0.0%
Financing Cash Flow
-10.2M
↑ 0.0%
Q2 FY22Q/Q Change
Operating Cash Flow
10.0M
↑ 57.25%
Investing Cash Flow
-8.9M
↑ 114.28%
Financing Cash Flow
-26.0M
↑ 156.18%
Q3 FY22Q/Q Change
Operating Cash Flow
5.8M
↓ 42.21%
Investing Cash Flow
-7.5M
↓ 16.3%
Financing Cash Flow
-5.4M
↓ 79.41%

Technicals Summary

Sell

Neutral

Buy

PROCAPS GROUP SA is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
PROCAPS GROUP SA
PROCAPS GROUP SA
-7.58%
-34.21%
-49.82%
-58.14%
-58.14%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-12.02%
-24.82%
-2.11%
-26.64%
-2.82%
Zoetis Inc.
Zoetis Inc.
-8.25%
11.42%
-3.62%
18.19%
98.12%
Viatris Inc.
Viatris Inc.
-2.72%
-18.56%
-25.79%
-44.28%
-44.28%
Catalent, Inc.
Catalent, Inc.
-25.94%
-21.32%
-63.98%
-52.24%
-4.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
PROCAPS GROUP SA
PROCAPS GROUP SA
9.88
9.88
NA
0.33
0.46
0.07
0.0
-0.01
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
148.68
148.68
1.87
1.93
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
37.47
37.47
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.82
5.82
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.21
16.21
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
PROCAPS GROUP SA
PROCAPS GROUP SA
Buy
$479.5M
-58.14%
9.88
10.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$9.0B
-2.82%
148.68
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$76.4B
98.12%
37.47
25.59%
Viatris Inc.
Viatris Inc.
Hold
$10.9B
-44.28%
5.82
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.7B
-4.13%
16.21
8.62%

Institutional Holdings

  • Compass Group LLC

    0.48%
  • Millennium Management LLC

    0.06%
  • Geode Capital Management, LLC

    0.02%
  • State Street Corporation

    0.01%

Company Information

Procaps is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in Latin America and, as of December 31, 2020, had more than 4,700 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.

Organization
PROCAPS GROUP SA
Employees
5500
CEO
Mr. Ruben Minski
Industry
Healthcare

FAQs